10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2010 | |||
Consolidated Statement of Earnings | |||
Period Ending Dec 31, 2010 10-K (Filed: Feb 18, 2011) | |||
| (In Millions, except shares in Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |
| Net Sales | $ 35,167 | 30,765 | 29,528 |
| Cost of products sold | 14,665 | 13,209 | 12,612 |
| Research and development | 3,724 | 2,744 | 2,689 |
| Acquired in-process research and development | 313 | 170 | 97 |
| Selling, general and administrative | 10,376 | 8,406 | 8,436 |
| Total Operating Cost and Expenses | 29,079 | 24,529 | 23,834 |
| Operating Earnings | 6,088 | 6,236 | 5,694 |
| Interest expense | 553 | 520 | 528 |
| Interest (income) | (105) | (138) | (201) |
| (Income) from the TAP Pharmaceutical Products Inc. joint venture | (119) | ||
| Net foreign exchange (gain) loss | (11) | 36 | 84 |
| Other (income) expense, net | (62) | (1,375) | (455) |
| Earnings from Continuing Operations Before Taxes | 5,713 | 7,194 | 5,856 |
| Taxes on Earnings from Continuing Operations | 1,087 | 1,448 | 1,122 |
| Earnings from continuing operations | 4,626 | 5,746 | 4,734 |
| Gain on Sale of Discontinued Operations, net of taxes | 147 | ||
| Net Earnings | 4,626 | 5,746 | 4,881 |
| Basic Earnings Per Common Share -- | |||
| Continuing Operations (in dollars per share) | 2.98 | 3.71 | 3.06 |
| Gain on Sale of Discontinued Operations, net of taxes (in dollars per share) | 0.10 | ||
| Net Earnings (in dollars per share) | 2.98 | 3.71 | 3.16 |
| Diluted Earnings Per Common Share -- | |||
| Continuing Operations | 2.96 | 3.69 | 3.03 |
| Gain on Sale of Discontinued Operations, net of taxes (in dollars per share) | 0.09 | ||
| Net Earnings | 2.96 | 3.69 | 3.12 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,546,400 | 1,546,983 | 1,545,355 |
| Dilutive Common Stock Options and Awards (in shares) | 9,622 | 8,143 | 15,398 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options and Awards (in shares) | 1,556,022 | 1,555,126 | 1,560,753 |
| Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 29,403 | 66,189 | 30,579 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2010 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2010 10-K (Filed: Feb 18, 2011) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |
| Cash Flow From (Used in) Operating Activities of Continuing Operations: | |||
| Net earnings | $ 4,626,172 | 5,745,838 | 4,880,719 |
| Less: Gain on sale of discontinued operations | 146,503 | ||
| Earnings from continuing operations | 4,626,172 | 5,745,838 | 4,734,216 |
| Adjustments to reconcile earnings from continuing operations to net cash from operating activities of continuing operations - | |||
| Depreciation | 1,207,450 | 1,210,977 | 1,051,728 |
| Amortization of intangible assets | 1,416,855 | 878,533 | 787,101 |
| Derecognition of a contingent liability associated with the conclusion of the TAP Pharmaceutical Products Inc. joint venture | (797,130) | ||
| Share-based compensation | 387,183 | 366,357 | 347,015 |
| Gain on dissolution of the TAP Pharmaceutical Products Inc. joint venture | (94,248) | ||
| Acquired in-process research and development | 313,200 | 170,000 | 97,256 |
| Investing and financing (gains) losses, net | 126,337 | 41,967 | 111,238 |
| Trade receivables | (394,665) | (387,749) | (948,314) |
| Inventories | 139,857 | 230,555 | (257,476) |
| Prepaid expenses and other assets | 553,145 | (386,889) | 436,218 |
| Trade accounts payable and other liabilities | 572,533 | (374,715) | 569,056 |
| Income taxes | (212,086) | 577,416 | 160,830 |
| Net Cash From Operating Activities of Continuing Operations | 8,735,981 | 7,275,160 | 6,994,620 |
| Cash Flow From (Used in) Investing Activities of Continuing Operations: | |||
| Acquisitions of businesses and technologies, net of cash acquired | (9,433,243) | (2,370,630) | (250,000) |
| Acquisitions of property and equipment | (1,015,075) | (1,089,048) | (1,287,724) |
| Sales of Boston Scientific common stock | 318,645 | ||
| Purchases of investment securities | (805,932) | (248,970) | (923,937) |
| Proceeds from sales of investment securities | 954,361 | 16,306 | 130,586 |
| Deposit of restricted funds | (1,870,000) | ||
| Other | (18,426) | (6,368) | (75,061) |
| Net Cash (Used in) Investing Activities of Continuing Operations | (12,188,315) | (3,698,710) | (2,087,491) |
| Cash Flow From (Used in) Financing Activities of Continuing Operations: | |||
| (Repayments of) proceeds from issuance of short-term debt and other | (203,854) | 3,217,331 | (324,739) |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 4,000,000 | 3,000,000 | |
| Repayments of long-term debt and debt with maturities over 3 months | (1,673,998) | (2,483,176) | (913,948) |
| Purchases of common shares | (866,825) | (826,345) | (1,081,806) |
| Proceeds from stock options exercised, including income tax benefit | 328,411 | 508,669 | 1,008,843 |
| Dividends paid | (2,671,475) | (2,414,460) | (2,174,252) |
| Net Cash (Used in) From Financing Activities of Continuing Operations | (1,087,741) | 1,002,019 | (3,485,902) |
| Effect of exchange rate changes on cash and cash equivalents | (620,893) | 118,848 | (115,160) |
| Net cash provided from the sale of discontinued operations | 349,571 | ||
| Net (Decrease) Increase in Cash and Cash Equivalents | (5,160,968) | 4,697,317 | 1,655,638 |
| Cash and Cash Equivalents, Beginning of Year | 8,809,339 | 4,112,022 | |
| Cash and Cash Equivalents, End of Year | 3,648,371 | 8,809,339 | 4,112,022 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ABBOTT LABORATORIES | ||
Ticker: ABT Fiscal Year: 2010 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2010 10-K (Filed: Feb 18, 2011) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2010 | Dec 31, 2009 | |
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 3,648,371 | 8,809,339 |
| Investments, primarily time deposits and certificates of deposit | 1,803,079 | 1,122,709 |
| Restricted funds, primarily U.S. treasury bills | 1,872,490 | |
| Trade receivables, less allowances of - 2010: $388,564; 2009: $311,546; 2008: $263,632 | 7,184,034 | 6,541,941 |
| Inventories: | ||
| Finished products | 2,058,735 | 2,289,280 |
| Work in process | 383,580 | 448,487 |
| Materials | 746,419 | 527,110 |
| Total inventories | 3,188,734 | 3,264,877 |
| Deferred income taxes | 3,076,051 | 2,364,142 |
| Other prepaid expenses and receivables | 1,544,770 | 1,210,883 |
| Total Current Assets | 22,317,529 | 23,313,891 |
| Investments | 302,049 | 1,132,866 |
| Property and Equipment, at Cost: | ||
| Land | 648,988 | 546,204 |
| Buildings | 4,334,236 | 4,010,439 |
| Equipment | 11,813,618 | 11,325,450 |
| Construction in progress | 577,460 | 604,813 |
| Property and Equipment, at Cost | 17,374,302 | 16,486,906 |
| Less: accumulated depreciation and amortization | 9,403,346 | 8,867,417 |
| Net Property and Equipment | 7,970,956 | 7,619,489 |
| Intangible Assets, net of amortization | 12,151,628 | 6,291,989 |
| Goodwill | 15,930,077 | 13,200,174 |
| Deferred Income Taxes and Other Assets | 790,027 | 858,214 |
| Total Assets | 59,462,266 | 52,416,623 |
| Liabilities and Shareholders' Investment | ||
| Current Liabilities: | ||
| Short-term borrowings | 4,349,796 | 4,978,438 |
| Trade accounts payable | 1,535,759 | 1,280,542 |
| Salaries, wages and commissions | 1,328,665 | 1,117,410 |
| Other accrued liabilities | 6,014,772 | 4,363,032 |
| Dividends payable | 680,749 | 620,640 |
| Income taxes payable | 1,307,723 | 442,140 |
| Obligation in connection with conclusion of the TAP Pharmaceutical Products Inc. joint venture | 36,105 | |
| Current portion of long-term debt | 2,044,970 | 211,182 |
| Total Current Liabilities | 17,262,434 | 13,049,489 |
| Long-term Debt | 12,523,517 | 11,266,294 |
| Post-employment Obligations and Other Long-term Liabilities | 7,199,851 | 5,202,111 |
| Commitments and Contingencies | ||
| Shareholders' Investment: | ||
| Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued | ||
| Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2010: 1,619,689,876; 2009: 1,612,683,987; 2008: 1,601,580,899 | 8,744,703 | 8,257,873 |
| Common shares held in treasury, at cost - Shares: 2010: 72,705,928; 2009: 61,516,398; 2008: 49,147,968 | (3,916,823) | (3,310,347) |
| Earnings employed in the business | 18,927,101 | 17,054,027 |
| Accumulated other comprehensive income (loss) | (1,366,846) | 854,074 |
| Total Abbott Shareholders' Investment | 22,388,135 | 22,855,627 |
| Noncontrolling Interests in Subsidiaries | 88,329 | 43,102 |
| Total Shareholders' Investment | 22,476,464 | 22,898,729 |
| Total Liabilities and Shareholders' Investment | 59,462,266 | 52,416,623 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2010 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |